Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:08 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT04905407 · Syros Pharmaceuticals · PHASE2 · terminated · last registry update 2025-02-24 · Acute myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “As per sponsor decision, the study was terminated.” | Open Targets' class: business administrative | Registry record, Syros Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against RARB in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-12-13Results posted on the registry: Syros Pharmaceuticals, Tamibarotene + Azacitidine (NCT02807558)
- 2024-12-09Also stopped (terminated): Taiho Oncology, Inc., TAS1440 + TAS1440 + ATRA (NCT04282668)
- 2024-05-08Also stopped (terminated): University Hospital Regensburg, low-dose Azacitidine + Pioglitazone (NCT02942758)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision